APA

Kim K., Kim S., Sasase N., Taniguchi M., Harada S., Kinoshita K., Kim S., Akimoto Y., Shikata M., Kimura N., Izawa S., Ohtani A., Nakao K., Motojima M., Kinoshita M., Hirai M., Ohzu M., Hirooka T., Nabeshima S., Ishii F., Tanaka K. & Hotta H. (20061215). 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. : Journal of clinical pharmacy and therapeutics.

Chicago

Kim K-I, Kim S-R, Sasase N, Taniguchi M, Harada S, Kinoshita K, Kim S-H, Akimoto Y, Shikata M, Kimura N, Izawa S, Ohtani A, Nakao K, Motojima M, Kinoshita M, Hirai M, Ohzu M, Hirooka T, Nabeshima S, Ishii F, Tanaka K and Hotta H. 20061215. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. : Journal of clinical pharmacy and therapeutics.

Harvard

Kim K., Kim S., Sasase N., Taniguchi M., Harada S., Kinoshita K., Kim S., Akimoto Y., Shikata M., Kimura N., Izawa S., Ohtani A., Nakao K., Motojima M., Kinoshita M., Hirai M., Ohzu M., Hirooka T., Nabeshima S., Ishii F., Tanaka K. and Hotta H. (20061215). 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. : Journal of clinical pharmacy and therapeutics.

MLA

Kim K-I, Kim S-R, Sasase N, Taniguchi M, Harada S, Kinoshita K, Kim S-H, Akimoto Y, Shikata M, Kimura N, Izawa S, Ohtani A, Nakao K, Motojima M, Kinoshita M, Hirai M, Ohzu M, Hirooka T, Nabeshima S, Ishii F, Tanaka K and Hotta H. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. : Journal of clinical pharmacy and therapeutics. 20061215.